Stroke is a medical emergency that can leave people with lasting disability. Many patients arrive at hospitals with a blocked artery in the brain. Doctors often use a procedure called endovascular thrombectomy to remove the clot. This trial looked at whether giving a specific drug called tenecteplase before the procedure helps patients recover better. The study involved 391 adults who had an ischemic stroke between 4.5 and 24 hours after their last known normal moment. These patients had a blockage in a major artery in the brain and had some brain tissue that could still be saved. The research took place across 40 centers in China.
The researchers divided patients into two groups. One group received intravenous tenecteplase before the clot removal procedure. The other group received only the clot removal procedure. The main goal was to see if the drug helped patients achieve functional independence. This means being able to care for themselves and move around without major help. The team also tracked how many people died and how many had bleeding in the brain.
The results showed no clear benefit from adding the drug. At 90 days, 44.2 percent of patients in the drug group were functionally independent. In the group that had only the procedure, 43.2 percent reached the same level of recovery. The difference was very small and not statistically significant. The number of deaths was slightly lower in the drug group, but the difference was not reported as significant. However, the risk of bleeding in the brain was higher in the group that received the drug. About 5.1 percent had symptomatic bleeding compared to 2.6 percent in the other group.
Safety was a key concern because the drug increased the chance of bleeding. While the number of deaths did not rise significantly, the higher rate of bleeding is an important safety signal. The study did not report any other serious adverse events or reasons for stopping the treatment. Because the trial was limited to patients with a specific type of blockage and a specific time window, the results apply only to that group.
This single study suggests that adding tenecteplase before clot removal does not improve outcomes for patients with proximal middle cerebral artery occlusion. Patients and families should not expect better recovery from this specific combination. The findings do not change the standard of care for everyone, but they do suggest that this specific drug addition may not be necessary for this specific patient group. More research is needed to see if different doses or different patient groups might benefit. Until then, doctors will continue to weigh the risks and benefits carefully for each individual case.